PMID- 21204768
OWN - NLM
STAT- MEDLINE
DCOM- 20110527
LR  - 20131121
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 25
IP  - 6
DP  - 2010 Dec
TI  - Experimental study on the therapeutic effect of positron emission tomography 
      agent [(1)(8)F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model.
PG  - 733-40
LID - 10.1089/cbr.2010.0818 [doi]
AB  - The purpose of this study was to assess the therapeutic effect of positron 
      emission tomography agent [(1)(8)F]-labeled 2-deoxy-2-fluoro-d-glucose ((1)(8)F-FDG) in a 
      colorectal cancer mouse model. Three (3) tumor-bearing mice groups were treated 
      with different doses of (1)(8)F-FDG. Mice were imaged by positron emission tomography 
      with (1)(8)F-FDG before and after treatment weekly and the tumor growth rate was 
      calculated. Tumor, brain, heart, and kidney of mice were analyzed for expression 
      of glucose transporters and vascular endothelial growth factor (VEGF) by 
      immunofluorescent staining, and the presence of apoptosis was detected by 
      terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) method. All 
      3 treated groups showed significant (1)(8)F-FDG reduction compared with the control 
      group (p < 0.05). With higher treatment dose, better treatment response was 
      observed. The tumor growth rate of all 3 treated groups was also significantly 
      decreased after treatment (p < 0.05). Immunohistochemistry showed that tumors 
      expressed more glucose transporters than in brain, heart, and kidney. The (1)(8)F-FDG 
      treatment of mice resulted in apoptotic cell death in all 3 treated groups, which 
      showed significant higher apoptotic cells than the control group (p < 0.05). The 
      study suggests that (1)(8)F-FDG has a therapeutic effect in colonic cancer animal 
      model, which indicates the potential for the development of positron therapy for 
      colonic cancer and other cancers.
FAU - Fang, Shengwei
AU  - Fang S
AD  - Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Wang, Jing
AU  - Wang J
FAU - Jiang, Han
AU  - Jiang H
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Xi, Wang
AU  - Xi W
FAU - Zhao, Chunlei
AU  - Zhao C
FAU - Tian, Mei
AU  - Tian M
FAU - Zhang, Hong
AU  - Zhang H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Glucose Transporter Type 1)
RN  - 0 (Glucose Transporter Type 3)
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Animal Structures/metabolism
MH  - Animals
MH  - Apoptosis/radiation effects
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/metabolism/pathology/*radiotherapy
MH  - Female
MH  - Fluorodeoxyglucose F18/metabolism/*therapeutic use
MH  - Glucose Transporter Type 1/metabolism
MH  - Glucose Transporter Type 3/metabolism
MH  - Glucose Transporter Type 4/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Necrosis/pathology
MH  - Positron-Emission Tomography
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - *Xenograft Model Antitumor Assays
EDAT- 2011/01/06 06:00
MHDA- 2011/05/28 06:00
CRDT- 2011/01/06 06:00
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2011/05/28 06:00 [medline]
AID - 10.1089/cbr.2010.0818 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2010 Dec;25(6):733-40. doi: 10.1089/cbr.2010.0818.